Replies to post #770727 on NorthWest Biotherapeutics Inc (NWBO)

[dennisdave]

In essence, NWBO's development of a broader, automated system via Flaskworks is a strategic move to future-proof its manufacturing capabilities, capitalize on the growing CAR T cell market, and leverage its existing automation expertise to address widespread challenges in cell therapy production, ultimately aiming for wider applicability, scalability, and cost-effectiveness.

BS x2


Adapting Flaskworks for CAR T would require significant additional development and validation, which hasn't been disclosed.
There is no public confirmation that NWBO is entering CAR T manufacturing. The patent allows for broader use but does not confirm current strategic intent to pursue CAR T commercially. NWBO has made no announcements or SEC filings about CAR T plan and if they would they would be screwing shareholders over AGAIN